The significance of defining preclinical or prodromal Parkinson's disease
被引:44
|
作者:
Olanow, C. Warren
论文数: 0引用数: 0
h-index: 0
机构:
Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA
Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USAMt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA
Olanow, C. Warren
[1
,2
]
Obeso, Jose A.
论文数: 0引用数: 0
h-index: 0
机构:
Univ Navarra, Dept Neurol, E-31080 Pamplona, SpainMt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA
Obeso, Jose A.
[3
]
机构:
[1] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA
[2] Mt Sinai Sch Med, Dept Neurosci, New York, NY 10029 USA
A body of clinical and pathologic evidence supports the concept that there a pre-Parkinson state exists prior to the time when Parkinson's disease (PD) can be formally diagnosed. The ability to define a the preclinical or prodromal PD state has many important implications. First, understanding the timing and sequence of pathologic change that occurs in PD could provide important clues as to the etiology and pathogenesis of PD, and provide insight into cell vulnerability factors. Second, defining a population of patients with preclinical PD would provide a potentially important group of subjects for clinical trials attempting to define disease-modifying therapies. And, finally, being able to determine that a person has PD at an earlier time point than is currently possible would permit the introduction of a putative disease-modifying therapy at a time when it could have more profound and long-lasting effects. This paper reviews the clinical significance of defining preclinical PD. (C) 2012 Movement Disorder Society
机构:
Univ Toronto, Toronto, ON, Canada
Toronto Western Hosp, Morton & Gloria Shulman Movement Disorders Clin, Toronto, ON M5T 2S8, Canada
Toronto Western Hosp, Edmond J Safra Program Parkinsons Dis, Toronto, ON M5T 2S8, CanadaUniv Toronto, Toronto, ON, Canada